- Home
- ATNM vs ZGM Comparison
ATNM vs ZGM Comparison
Compare ATNM & ZGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- ZGM
- Stock Information
- Founded
- ATNM 2000
- ZGM 2019
- Country
- ATNM United States
- ZGM Macau
- Employees
- ATNM N/A
- ZGM N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- ZGM Professional Services
- Sector
- ATNM Health Care
- ZGM Consumer Discretionary
- Exchange
- ATNM Nasdaq
- ZGM Nasdaq
- Market Cap
- ATNM 50.2M
- ZGM 47.4M
- IPO Year
- ATNM N/A
- ZGM 2025
- Fundamental
- Price
- ATNM $1.63
- ZGM N/A
- Analyst Decision
- ATNM Strong Buy
- ZGM
- Analyst Count
- ATNM 2
- ZGM 0
- Target Price
- ATNM $4.50
- ZGM N/A
- AVG Volume (30 Days)
- ATNM 130.6K
- ZGM 1.3M
- Earning Date
- ATNM 11-13-2025
- ZGM 01-01-0001
- Dividend Yield
- ATNM N/A
- ZGM N/A
- EPS Growth
- ATNM N/A
- ZGM 401.52
- EPS
- ATNM N/A
- ZGM 0.17
- Revenue
- ATNM N/A
- ZGM $3,620,780.00
- Revenue This Year
- ATNM N/A
- ZGM N/A
- Revenue Next Year
- ATNM N/A
- ZGM N/A
- P/E Ratio
- ATNM N/A
- ZGM $23.62
- Revenue Growth
- ATNM N/A
- ZGM 211.78
- 52 Week Low
- ATNM $1.03
- ZGM $2.00
- 52 Week High
- ATNM $2.41
- ZGM $4.51
- Technical
- Relative Strength Index (RSI)
- ATNM 46.73
- ZGM N/A
- Support Level
- ATNM $1.52
- ZGM N/A
- Resistance Level
- ATNM $1.70
- ZGM N/A
- Average True Range (ATR)
- ATNM 0.07
- ZGM 0.00
- MACD
- ATNM -0.01
- ZGM 0.00
- Stochastic Oscillator
- ATNM 36.71
- ZGM 0.00
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.